Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics granted 7,000 stock options and 3,500 RSUs to a new hire as a material inducement for employment, adhering to Nasdaq rules.
- On July 20, 2026, Atrium Therapeutics, Inc. awarded inducement grants to one new non-executive employee under its 2026 Employment Inducement Incentive Award Plan .
- The Board's Human Capital Management Committee approved the awards, which were granted outside stockholder-approved plans per Nasdaq Listing Rule 5635.
- With an exercise price of $11.76, the employee received 7,000 stock options and 3,500 restricted stock units, with 25% vesting on the first anniversary and remainder over subsequent years.
- Atrium specializes in RNA therapeutics for cardiomyopathies, developing two precision cardiology candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy.
- Utilizing small interfering RNA, the Company's platform is designed to target underlying drivers of genetically driven cardiac diseases through non-viral delivery technology.
22 Articles
22 Articles
Missoulian
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material…
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company’s common stock to four newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of di…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
